JPH0544930B2 - - Google Patents
Info
- Publication number
- JPH0544930B2 JPH0544930B2 JP85188689A JP18868985A JPH0544930B2 JP H0544930 B2 JPH0544930 B2 JP H0544930B2 JP 85188689 A JP85188689 A JP 85188689A JP 18868985 A JP18868985 A JP 18868985A JP H0544930 B2 JPH0544930 B2 JP H0544930B2
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- rheumatism
- treats
- interfaeron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000008070 Interferon-gamma Human genes 0.000 claims abstract description 11
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 11
- 229940044627 gamma-interferon Drugs 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 27
- 229940124597 therapeutic agent Drugs 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
- 102000014150 Interferons Human genes 0.000 claims description 9
- 108010050904 Interferons Proteins 0.000 claims description 9
- 210000000265 leukocyte Anatomy 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 5
- 201000003068 rheumatic fever Diseases 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 206010036030 Polyarthritis Diseases 0.000 claims description 4
- 229940047124 interferons Drugs 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 206010034464 Periarthritis Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 238000007919 intrasynovial administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 16
- 208000025747 Rheumatic disease Diseases 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 20
- 239000013543 active substance Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 239000003435 antirheumatic agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008685 Chondritis Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 208000030430 juvenile chronic polyarthritis Diseases 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- ROSJKFFLIXTTAW-UHFFFAOYSA-N n,n-bis(2-chloroethyl)aniline Chemical compound ClCCN(CCCl)C1=CC=CC=C1 ROSJKFFLIXTTAW-UHFFFAOYSA-N 0.000 description 1
- 230000007772 nodular growth Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
ãçºæã®å±ããæè¡åéã
æ¬çºæã¯ãγâã€ã³ã¿ããšãã³ãå«æãããªãŠ
ãŒããçæ²»çå€ã«é¢ãããã®ã§ããã
ãŒããçæ²»çå€ã«é¢ãããã®ã§ããã
å
šãŠã®å
¬ç¥ã€ã³ã¿ããšãã³ã¯ããã®æ§é éºäŒå
ã®ãã¯ã¬ãªããé åéã®ã¿ãªããããã®ã¢ããé ž
é åéã®åææ§ã«åºã¥ããŠïŒã€ã®çŸ€ïŒããªãã¡Î±
âIFNïŒÎ²âIFNããã³Î³âIFNãšåŒã°ããïŒã€
ã®çŸ€ïŒã«æ確ã«åé¡ãããã
ã®ãã¯ã¬ãªããé åéã®ã¿ãªããããã®ã¢ããé ž
é åéã®åææ§ã«åºã¥ããŠïŒã€ã®çŸ€ïŒããªãã¡Î±
âIFNïŒÎ²âIFNããã³Î³âIFNãšåŒã°ããïŒã€
ã®çŸ€ïŒã«æ確ã«åé¡ãããã
䜿çšããçšèªã¯ããžãšãŒã»ãã«ã»ã¯ïŒ1983ïŒã«
ããã¢ãŒããã¹ã»ãªãã»ãã€ãããžãŒã第77å·»ã
第283ã285é ã«é瀺ããããã€ã³ã¿ããšãã³åœä»€
å§å¡äŒãã®ææ°ã®ææ¡ã«ãããã€ãŠãããäžèšã®
äž»ããåºæºã«å ããγâIFN矀ãç¹æ§åããã«
ã¯ãä»ã®äž¡IFN矀ã«å¯Ÿããå ç«åŠç亀éåå¿ã瀺
ããããã€Î±âIFNããã³Î²âIFNãšç°ãªãPHïŒ
ã«ãããŠçç©åŠçã«äžå®å®ã§ããç¹ãæããããš
ãã§ããã
ããã¢ãŒããã¹ã»ãªãã»ãã€ãããžãŒã第77å·»ã
第283ã285é ã«é瀺ããããã€ã³ã¿ããšãã³åœä»€
å§å¡äŒãã®ææ°ã®ææ¡ã«ãããã€ãŠãããäžèšã®
äž»ããåºæºã«å ããγâIFN矀ãç¹æ§åããã«
ã¯ãä»ã®äž¡IFN矀ã«å¯Ÿããå ç«åŠç亀éåå¿ã瀺
ããããã€Î±âIFNããã³Î²âIFNãšç°ãªãPHïŒ
ã«ãããŠçç©åŠçã«äžå®å®ã§ããç¹ãæããããš
ãã§ããã
γâIFNã¯å
ç«ç³»ã®ïŒŽâãªã³ãçã«ããè€éãª
éçšã§ããã²ã³ãŸãã¯ç¹å®æäœã§ã®åºæã«éãïŒ
矀ã®ä»ã®ãã¢ã¯ã¿ïŒåªäœïŒãšå ±ã«æŸåºããããã
ãã€ãŠåæã«ãªã³ããã³ãšã称ããããããã
ã«ãγâIFNãæ§æçã«ç£çããåŸæ¥ååšããå
å®ããããŸãã¯åœ¢è³ªè»¢æããã现èã©ã€ã³ã¯ãã
ãšãã°ãšãã»ããžã€çã«ãããžã€ãŒãã«ã»ã€ããŠ
ãããžãŒã第130å·»ã第1683â1686é ããã³ãš
ãŒã»ããããã¯çã«ãããžã€ãŒãã«ã»ã€ããŠãã
ãžãŒã第131å·»ã第794â800é ã«èšèŒãããŠããã
éçšã§ããã²ã³ãŸãã¯ç¹å®æäœã§ã®åºæã«éãïŒ
矀ã®ä»ã®ãã¢ã¯ã¿ïŒåªäœïŒãšå ±ã«æŸåºããããã
ãã€ãŠåæã«ãªã³ããã³ãšã称ããããããã
ã«ãγâIFNãæ§æçã«ç£çããåŸæ¥ååšããå
å®ããããŸãã¯åœ¢è³ªè»¢æããã现èã©ã€ã³ã¯ãã
ãšãã°ãšãã»ããžã€çã«ãããžã€ãŒãã«ã»ã€ããŠ
ãããžãŒã第130å·»ã第1683â1686é ããã³ãš
ãŒã»ããããã¯çã«ãããžã€ãŒãã«ã»ã€ããŠãã
ãžãŒã第131å·»ã第794â800é ã«èšèŒãããŠããã
ããç²è£œÎ³âIFNãåŸãããã®å¥œé©ãªæ¹æ³ã¯æ¬¡
ã®ããã«èšèŒãããŠãããåºçºç©è³ªãšããŠã¯ä¿å
è¡æ¶²ã®ãªã³ãçãªãããªè¡æŒ¿ãã©ã¯ã·ãšã³ïŒãã
ããããããã€ãŒã³ãŒããïŒã䜿çšãããããé
ããŠ600ã800ïœã«ãããæ éãªé å¿åé¢ã«ããè¡
挿æ®æž£ããåé¢ããããã¬ããåããå šçœè¡çã
äºåå æž©ãããåªäœäžãžçŽ°è5000000åïŒmlã®å¯
床ã«ãŠæžæ¿ãããããã®çŽ°èæžæ¿ç©ãããããã
é©åœãªå¹é€å®¹åšã«ãããŠããã²ã³ïŒããšãã°ãã€
ãããã°ã«ããã³ïŒããã³ãã«ãã«ãšã¹ãã«ïŒã
ãšãã°ãã«ãã«ããªã¹ãã«é ¢é žïŒïŒPMAïŒã®æ·»å
åŸã«37âã«ãŠæ¯ãšãæ©ã§70æéå¹é€ãããγâã€
ã³ã¿ããšãã³å«æã®å¹é€ç©ãé å¿åé¢ã«ãã€ãŠå
åãããããåŸã«äœ¿çšãããŸã§ïŒâã«ãŠè²¯èµãã
ããšãã§ãããéåžžããã®ããã«åŸããã調補ç©
ã¯çŽ10000åœéåºæºåäœã®Î³âIFNãïŒmlåœãã«
å«æããã
ã®ããã«èšèŒãããŠãããåºçºç©è³ªãšããŠã¯ä¿å
è¡æ¶²ã®ãªã³ãçãªãããªè¡æŒ¿ãã©ã¯ã·ãšã³ïŒãã
ããããããã€ãŒã³ãŒããïŒã䜿çšãããããé
ããŠ600ã800ïœã«ãããæ éãªé å¿åé¢ã«ããè¡
挿æ®æž£ããåé¢ããããã¬ããåããå šçœè¡çã
äºåå æž©ãããåªäœäžãžçŽ°è5000000åïŒmlã®å¯
床ã«ãŠæžæ¿ãããããã®çŽ°èæžæ¿ç©ãããããã
é©åœãªå¹é€å®¹åšã«ãããŠããã²ã³ïŒããšãã°ãã€
ãããã°ã«ããã³ïŒããã³ãã«ãã«ãšã¹ãã«ïŒã
ãšãã°ãã«ãã«ããªã¹ãã«é ¢é žïŒïŒPMAïŒã®æ·»å
åŸã«37âã«ãŠæ¯ãšãæ©ã§70æéå¹é€ãããγâã€
ã³ã¿ããšãã³å«æã®å¹é€ç©ãé å¿åé¢ã«ãã€ãŠå
åãããããåŸã«äœ¿çšãããŸã§ïŒâã«ãŠè²¯èµãã
ããšãã§ãããéåžžããã®ããã«åŸããã調補ç©
ã¯çŽ10000åœéåºæºåäœã®Î³âIFNãïŒmlåœãã«
å«æããã
γâIFNå«æéã¯ãé©åœãªæšè现èïŒããšãã°
WISHïŒã«ãããCPEâæžå°è©Šéšã«ããè©ŠéšãŠã€
ã«ã¹ïŒããšãã°ãããºãã®EMCïŒãçšããŠãã·
ãšãã«ã»ã€ã³ã¹ãã€ããŠãŒãã»ãªãã»ãã«ã¹
ïŒUSAïŒã®åºæºæ³Gg23â901â530ã«ãããã調
補ç©ã®æãŠã€ã«ã¹æŽ»æ§ãšããŠæž¬å®ãããã
WISHïŒã«ãããCPEâæžå°è©Šéšã«ããè©ŠéšãŠã€
ã«ã¹ïŒããšãã°ãããºãã®EMCïŒãçšããŠãã·
ãšãã«ã»ã€ã³ã¹ãã€ããŠãŒãã»ãªãã»ãã«ã¹
ïŒUSAïŒã®åºæºæ³Gg23â901â530ã«ãããã調
補ç©ã®æãŠã€ã«ã¹æŽ»æ§ãšããŠæž¬å®ãããã
γâIFN調補ç©ãåŸãããã®ä»ã®æ¹æ³ã¯ãã¯
ã€ã»ã±ãŒã»ã€ããçã«ãããææããã³å ç«ã
ïŒ1981幎10æïŒç¬¬34å·»ã第131â133é ããã³ç±³åœ
ç¹èš±ç¬¬4376821å·ã第4376822å·ããã³ç¬¬4460685
å·åå ¬å ±ã«èšèŒãããŠããã
ã€ã»ã±ãŒã»ã€ããçã«ãããææããã³å ç«ã
ïŒ1981幎10æïŒç¬¬34å·»ã第131â133é ããã³ç±³åœ
ç¹èš±ç¬¬4376821å·ã第4376822å·ããã³ç¬¬4460685
å·åå ¬å ±ã«èšèŒãããŠããã
ããγâIFN調補ç©ãåŸãããã®ä»ã®åºæ¬çæ¹
æ³ã¯ãé©åœãªãã¯ã¿ãŒã«ããããæ§é éºäŒåãç°
質宿䞻现èã«çµã¿èŸŒãããšãããªã€ãŠããããã®
çµæéºäŒåããæ§æçã«ãŸãã¯ç¹å®èªçºå€ã®æ·»å
ã®åŸã«å®¿äž»çŽ°èã«ããçºçŸããããããã«ãèªå°
ããããã¢ããé žé åã®åæãå¿ ç¶çã«ãããã
ãããªæ確ã«èŠå®ããããã¯ã¬ãªããé åãæ§é
éºäŒåã«ãããŠåé¡ãšãªãå ŽåãγâIFNåå
ïŒããªãã¡å®¿äž»çŽ°èã«ããçæããã調補ç©ïŒã¯
å¿ ãããã倩ç¶ã«çæããγâIFNãšã¯åäžã§ãª
ãããåŸåŠçãã«ããç¹å®äœçšãåŸãéã®ãã®å€
åã®å¯èœæ§ã¯ãããããèçœè³ªèšèšã«ããæ¡å€§ã
ããããã«ããæ§é éºäŒåã¯ååŠçãŸãã¯çååŠ
çãªå®å šåæãŸãã¯æ¹å€ã«ããå€åããããã
æ³ã¯ãé©åœãªãã¯ã¿ãŒã«ããããæ§é éºäŒåãç°
質宿䞻现èã«çµã¿èŸŒãããšãããªã€ãŠããããã®
çµæéºäŒåããæ§æçã«ãŸãã¯ç¹å®èªçºå€ã®æ·»å
ã®åŸã«å®¿äž»çŽ°èã«ããçºçŸããããããã«ãèªå°
ããããã¢ããé žé åã®åæãå¿ ç¶çã«ãããã
ãããªæ確ã«èŠå®ããããã¯ã¬ãªããé åãæ§é
éºäŒåã«ãããŠåé¡ãšãªãå ŽåãγâIFNåå
ïŒããªãã¡å®¿äž»çŽ°èã«ããçæããã調補ç©ïŒã¯
å¿ ãããã倩ç¶ã«çæããγâIFNãšã¯åäžã§ãª
ãããåŸåŠçãã«ããç¹å®äœçšãåŸãéã®ãã®å€
åã®å¯èœæ§ã¯ãããããèçœè³ªèšèšã«ããæ¡å€§ã
ããããã«ããæ§é éºäŒåã¯ååŠçãŸãã¯çååŠ
çãªå®å šåæãŸãã¯æ¹å€ã«ããå€åããããã
ããéºäŒåãçµã¿èŸŒãããã®å®¿äž»çŽ°èãšããŠ
ã¯ã现èïŒããšãã°ããžãŒã»ã·ã¢ã³ã¹çã«ãããž
ãŒã³ã第28å·»ã第55â64é ïŒ1984ïŒã«èšèŒããã
ãããªã€ãŒã»ã³ãªïŒã®ä»ã«é µæ¯ïŒããšãã°ãã¢ãŒ
ã«ã»ããªã³ã¯çã«ãããã¯ã¬ã€ãã¯ã»ã¢ã·ããã»
ãªãµãŒãã第11å·»ã第1819â1837é ïŒ1983ïŒã«èš
èŒããããããªãµãã«ããã»ã¹ã»ã»ã¬ãã·ãŒïŒãŸ
ãã¯çæ žçŽ°èïŒããšãã°ããšã¹ã»ãžãšãŒã»ã¹ã«ã
ã«çã«ããããã·ãŒãã€ã³ã°ã»ã¢ã«ãããã¯ã»ãµ
ã€ãšã³ã¹ã»USAã第80å·»ã第4654â4658é
ïŒ1983ïŒæãã¯ããŒã»ãããªãŠãŒã»ã°ã¬ãŒçã«ã
ãããŒãã€ãŒã第295å·»ã第503â508é ïŒ1982ïŒ
ã«èšèŒããããããªæ¯é£ãã ã¹ã¿ãŒã®åµçŽ°èïŒã
䜿çšããããšãã§ããã
ã¯ã现èïŒããšãã°ããžãŒã»ã·ã¢ã³ã¹çã«ãããž
ãŒã³ã第28å·»ã第55â64é ïŒ1984ïŒã«èšèŒããã
ãããªã€ãŒã»ã³ãªïŒã®ä»ã«é µæ¯ïŒããšãã°ãã¢ãŒ
ã«ã»ããªã³ã¯çã«ãããã¯ã¬ã€ãã¯ã»ã¢ã·ããã»
ãªãµãŒãã第11å·»ã第1819â1837é ïŒ1983ïŒã«èš
èŒããããããªãµãã«ããã»ã¹ã»ã»ã¬ãã·ãŒïŒãŸ
ãã¯çæ žçŽ°èïŒããšãã°ããšã¹ã»ãžãšãŒã»ã¹ã«ã
ã«çã«ããããã·ãŒãã€ã³ã°ã»ã¢ã«ãããã¯ã»ãµ
ã€ãšã³ã¹ã»USAã第80å·»ã第4654â4658é
ïŒ1983ïŒæãã¯ããŒã»ãããªãŠãŒã»ã°ã¬ãŒçã«ã
ãããŒãã€ãŒã第295å·»ã第503â508é ïŒ1982ïŒ
ã«èšèŒããããããªæ¯é£ãã ã¹ã¿ãŒã®åµçŽ°èïŒã
䜿çšããããšãã§ããã
ããã幟ã€ãã®ç³»ã«ãããŠÎ³âIFNã¯å¹é€æ¶²äž
ã«ïŒmlåœã100000åœéåºæºåäœä»¥äžã®æ¿åºŠãŸã§æ¿
ååããããæãã¯å®¿äž»èªèº«ã«ãããŠæ¿ååããŠ
现èã®èçœè³ªå«æéã«å¯Ÿã25ïŒ ãŸã§èç©ããã
ã«ïŒmlåœã100000åœéåºæºåäœä»¥äžã®æ¿åºŠãŸã§æ¿
ååããããæãã¯å®¿äž»èªèº«ã«ãããŠæ¿ååããŠ
现èã®èçœè³ªå«æéã«å¯Ÿã25ïŒ ãŸã§èç©ããã
äžèšæ¹æ³ã«ããåŸãããγâIFN調補ç©ã®æ¿å
åãŸãã¯ç²Ÿè£œã¯ã次ã®æ¹æ³ã«ããåã ã«ãŸãã¯çµ
ã¿åããŠè¡ãªãããšãã§ããïŒ ïŒ èª¿ç¯å€å質ã¬ã©ã¹ïŒCPGïŒãŸãã¯ã·ãªã«ã²
ã«ã ïŒ ã²ã«æ¿ŸéïŒããšãã°AcA54ãŸãã¯ã»ãã¢ã»
ã«S200ïŒã ïŒ ã€ãªã³äº€æã¯ãããã°ã©ãã€ãŒïŒCMâã»ã
ã¢ããŒã¹ãŸãã¯ãã¹ããªã»ã«ããŒã¹ãŸãã¯
DEAEâã»ã«ããŒã¹ïŒã ïŒ èŠªåæ§ã¯ãããã°ã©ãã€ãŒïŒCon âã»ã
ã¢ããŒã¹ãŸãã¯ããªââã»ãã¢ããŒã¹ãŸãã¯
Cuâãã¬ãŒãâã»ãã¢ããŒã¹ïŒã ïŒ å ç«èŠªåæ§ã¯ãããã°ã©ãã€ãŒïŒæâγâ
IFNâã»ãã¢ããŒã¹ïŒã ïŒ HPLCïŒããšãã°é転çžç©è³ªïŒã
åãŸãã¯ç²Ÿè£œã¯ã次ã®æ¹æ³ã«ããåã ã«ãŸãã¯çµ
ã¿åããŠè¡ãªãããšãã§ããïŒ ïŒ èª¿ç¯å€å質ã¬ã©ã¹ïŒCPGïŒãŸãã¯ã·ãªã«ã²
ã«ã ïŒ ã²ã«æ¿ŸéïŒããšãã°AcA54ãŸãã¯ã»ãã¢ã»
ã«S200ïŒã ïŒ ã€ãªã³äº€æã¯ãããã°ã©ãã€ãŒïŒCMâã»ã
ã¢ããŒã¹ãŸãã¯ãã¹ããªã»ã«ããŒã¹ãŸãã¯
DEAEâã»ã«ããŒã¹ïŒã ïŒ èŠªåæ§ã¯ãããã°ã©ãã€ãŒïŒCon âã»ã
ã¢ããŒã¹ãŸãã¯ããªââã»ãã¢ããŒã¹ãŸãã¯
Cuâãã¬ãŒãâã»ãã¢ããŒã¹ïŒã ïŒ å ç«èŠªåæ§ã¯ãããã°ã©ãã€ãŒïŒæâγâ
IFNâã»ãã¢ããŒã¹ïŒã ïŒ HPLCïŒããšãã°é転çžç©è³ªïŒã
察å¿ã®æ¹æ³ã¯ã¯ã€ã»ã±ãŒã»ã€ããçã«ãããã
ã·ãŒãã€ã³ã°ã»ãã·ãšãã«ã»ã¢ã«ãããŒã»ãµã€ãš
ã³ã¹ã»USAã第78å·»ã第1601ã1605é ïŒ1981ïŒ
ã«ããããããγïŒå ç«ïŒã€ã³ã¿ããšãã³ã®éšå
粟補ããã³ç¹æ§åãã«èšèŒãããæãã¯ããŒã»ã
ããã¯çã«ããEMBOãžã€ãŒãã«ã第ïŒå·»ã第
1527â1530é ïŒ1984ïŒãŸãã¯ãã€ãç¹èš±ç¬¬
3136166 A1å·å ¬å ±ã«èšèŒãããŠããã
ã·ãŒãã€ã³ã°ã»ãã·ãšãã«ã»ã¢ã«ãããŒã»ãµã€ãš
ã³ã¹ã»USAã第78å·»ã第1601ã1605é ïŒ1981ïŒ
ã«ããããããγïŒå ç«ïŒã€ã³ã¿ããšãã³ã®éšå
粟補ããã³ç¹æ§åãã«èšèŒãããæãã¯ããŒã»ã
ããã¯çã«ããEMBOãžã€ãŒãã«ã第ïŒå·»ã第
1527â1530é ïŒ1984ïŒãŸãã¯ãã€ãç¹èš±ç¬¬
3136166 A1å·å ¬å ±ã«èšèŒãããŠããã
é©åœãªçµã¿åãã«ããé»æ°æ³³åçãªåäžæ§ãŸã§
粟補ããããšãå¯èœã§ããããã®éåŸãããæé«
ã®æ¯æŽ»æ§ã¯100000000ã200000000åœéåºæºåäœã§
ããããŸãå¹³åçæ°å€ã¯10000000ã50000000åœé
åºæºåäœã§ãããèçœè³ªïŒmgåœã100000ã
200000000åœéåºæºåäœãå«æããïŒããªãã¡ã
1ÎŒgã®æŽ»æ§ç©è³ªã¯200000åœéåºæºåäœãŸã§ãå«æ
ããïŒéåžžã®èª¿è£œç©ãèšåºçã«äœ¿çšãããã
粟補ããããšãå¯èœã§ããããã®éåŸãããæé«
ã®æ¯æŽ»æ§ã¯100000000ã200000000åœéåºæºåäœã§
ããããŸãå¹³åçæ°å€ã¯10000000ã50000000åœé
åºæºåäœã§ãããèçœè³ªïŒmgåœã100000ã
200000000åœéåºæºåäœãå«æããïŒããªãã¡ã
1ÎŒgã®æŽ»æ§ç©è³ªã¯200000åœéåºæºåäœãŸã§ãå«æ
ããïŒéåžžã®èª¿è£œç©ãèšåºçã«äœ¿çšãããã
ä»ã®ã€ã³ã¿ããšãã³ãšåæ§ã«ãγâIFNãæãŠ
ã€ã«ã¹ãå¢æ®é²æ¢ããã³å ç«å€æ§ã®äœçšãæãã
ç©è³ªã§ãããã€ã³ãããã«ããã匷åãªå¢æ®é²æ¢
äœçšã«åºã¥ããαâIFNããã³Î²âIFNãšåæ§
ã«ãããã¯åŸæ¥æ®ãã©å°ãæªæ§çç¶ãæããæ£è
ã«ãããŠã®ã¿äœ¿çšããããããŒã»ã€ãŒã»ã±ã€ã ã
ãã³ãããªãŠãŒã»ãšãŒã»ã«ãŒã¿ãŒããã€ã³ã¿ããš
ãã³ããã³ãã®çšéããã¹ããªã³ã¬ãŒåºçããã«
ãªã³ã»ãã€ãã«ãã«ã°ãããŠãŒãšãŒã¯ãããŒããš
ãŒïŒ1984ïŒïŒã€ãŒã»ããã€ã€ãŒããã³ãšããã»ã·
ãšã¬ã³ã±ã³ïŒHrsgïŒããã€ã³ã¿ããšãã³ç³»ã®çç©
åŠãïŒ1983ïŒããšã«ã»ããŒã«ã»ãµã€ãšã³ã¹åºç瀟ã
ã¢ã ã¹ãã«ãã ãããŠãŒãšãŒã¯ããªãã¯ã¹ããªãŒ
ãïŒ1983ïŒãã
ã€ã«ã¹ãå¢æ®é²æ¢ããã³å ç«å€æ§ã®äœçšãæãã
ç©è³ªã§ãããã€ã³ãããã«ããã匷åãªå¢æ®é²æ¢
äœçšã«åºã¥ããαâIFNããã³Î²âIFNãšåæ§
ã«ãããã¯åŸæ¥æ®ãã©å°ãæªæ§çç¶ãæããæ£è
ã«ãããŠã®ã¿äœ¿çšããããããŒã»ã€ãŒã»ã±ã€ã ã
ãã³ãããªãŠãŒã»ãšãŒã»ã«ãŒã¿ãŒããã€ã³ã¿ããš
ãã³ããã³ãã®çšéããã¹ããªã³ã¬ãŒåºçããã«
ãªã³ã»ãã€ãã«ãã«ã°ãããŠãŒãšãŒã¯ãããŒããš
ãŒïŒ1984ïŒïŒã€ãŒã»ããã€ã€ãŒããã³ãšããã»ã·
ãšã¬ã³ã±ã³ïŒHrsgïŒããã€ã³ã¿ããšãã³ç³»ã®çç©
åŠãïŒ1983ïŒããšã«ã»ããŒã«ã»ãµã€ãšã³ã¹åºç瀟ã
ã¢ã ã¹ãã«ãã ãããŠãŒãšãŒã¯ããªãã¯ã¹ããªãŒ
ãïŒ1983ïŒãã
ãªãŠãŒããã«ãããŠã¯éååšç®¡ã«ãããçŒçã
ãã³æ©èœé害ãåé¡ãšãªãããšããã»ãããšã¹ã
ããªãŠãŒãã質ããã°ã¹ã¿ãã»ãã€ãã·ã€ãŒåºçã
ã¹ãããã¬ã«ããããŠãŒãšãŒã¯ïŒ1983ïŒãã蚺æâ
æ²»çâèšåºã®èŠ³ç¹ã«ããã°ã次ã®ããã«çš®ã æ§ã
ã§ããïŒççæ§ãªãŠãŒããçãå€æ§ãªãŠãŒããç
ããã³é¢ç¯å€ãªãŠãŒããçããªãŠãŒããçã®ç ç¶
ã«ã€ããŠã¯ããã«æ¬¡ã®ãã®ãæããããïŒå šèº«çŽ
ææ§çŒç¡ãé²è¡æ§å šèº«ç¡¬ç®çãç®èççãçµç¯æ§
åèåšå²çãå°¿é žé¢ç¯çããã³ç³ç°æ§è»éªšçãã
ããªãŠãŒã»ãã·ã¬ã³ãã«ããã¯ãªããããšã»ãã«
ãã«ããŒãããã¯ã«ã¿ãŒã»ãã»ã°ãªãã¿ãŒããã«
ãªã³ãããŠãŒãšãŒã¯ïŒ1982ïŒããççæ§ãªãŠãŒãã
çã«ã€ãæããããæ ¢æ§é¢ç¯çã®å ŽåãåäŸãè¥
幎局ã«çãã圢æ ã¯ãã°ãã°æ人ã«ããããã®ãš
ã¯ç°ãªã€ãŠããïŒããŒã»ãšã ã»ã¢ã³ããšã«ããè¥
幎æ§æ ¢æ§å€çºé¢ç¯çããArthr.Rheum.Supplã第
20å·»ã第176â180é ïŒ1977ïŒïŒãšããã»ãã«ã±ã³
ããããããè¥å¹Žæ§æ ¢æ§é¢ç¯çããã³ãã®äºåãã
Mušnch.med.Wschr.第126å·»ã第1076â1078é
ïŒ1984ïŒãã
ãã³æ©èœé害ãåé¡ãšãªãããšããã»ãããšã¹ã
ããªãŠãŒãã質ããã°ã¹ã¿ãã»ãã€ãã·ã€ãŒåºçã
ã¹ãããã¬ã«ããããŠãŒãšãŒã¯ïŒ1983ïŒãã蚺æâ
æ²»çâèšåºã®èŠ³ç¹ã«ããã°ã次ã®ããã«çš®ã æ§ã
ã§ããïŒççæ§ãªãŠãŒããçãå€æ§ãªãŠãŒããç
ããã³é¢ç¯å€ãªãŠãŒããçããªãŠãŒããçã®ç ç¶
ã«ã€ããŠã¯ããã«æ¬¡ã®ãã®ãæããããïŒå šèº«çŽ
ææ§çŒç¡ãé²è¡æ§å šèº«ç¡¬ç®çãç®èççãçµç¯æ§
åèåšå²çãå°¿é žé¢ç¯çããã³ç³ç°æ§è»éªšçãã
ããªãŠãŒã»ãã·ã¬ã³ãã«ããã¯ãªããããšã»ãã«
ãã«ããŒãããã¯ã«ã¿ãŒã»ãã»ã°ãªãã¿ãŒããã«
ãªã³ãããŠãŒãšãŒã¯ïŒ1982ïŒããççæ§ãªãŠãŒãã
çã«ã€ãæããããæ ¢æ§é¢ç¯çã®å ŽåãåäŸãè¥
幎局ã«çãã圢æ ã¯ãã°ãã°æ人ã«ããããã®ãš
ã¯ç°ãªã€ãŠããïŒããŒã»ãšã ã»ã¢ã³ããšã«ããè¥
幎æ§æ ¢æ§å€çºé¢ç¯çããArthr.Rheum.Supplã第
20å·»ã第176â180é ïŒ1977ïŒïŒãšããã»ãã«ã±ã³
ããããããè¥å¹Žæ§æ ¢æ§é¢ç¯çããã³ãã®äºåãã
Mušnch.med.Wschr.第126å·»ã第1076â1078é
ïŒ1984ïŒãã
æ®ãã©å€§æµã®ãªãŠãŒããçæ£è
ã®ç
åã¯æãã
ã§ãªãã®ã§ãäžè¬ã«åå çæ³ã¯äœ¿çšã§ããªããã±
ãŒã»ã¯ãªãŒã¬ãŒãããªãŠãŒããåŠã«ãããæ°ããª
æ²»çåçããMušnch.med.Wschrã第126å·»ã第
1084â1086é ïŒ1984ïŒããè¬ç©æäžæ²»çã«ãããŠã¯
åçš®ã®è¬å€ã䜿çšããããããã¯ïŒã€ã®çŸ€ã«åé¡
ããããšãã§ãããããªãã¡è¿ éã§ãããè¬å€ã
æåãããéã®ã¿äœçšããããšãã°ãµãªãã«é žã
ã€ã³ãã¡ã¿ã·ã³ããã³ã°ã«ã³ã³ã«ãã³ã€ãã®ãã
ãªå¯ŸçæãªãŠãŒããå€ãããã³ç åãæããŠæ²»ç
éå§åŸïŒãïŒé±éã§äœçšãçŸããããããã®å¹æ
ãæè¬åæ¢åŸã«ãæ°æéæç¶ãããããšãã°é
å¡©ãâããã·ã«ã¢ãã³ãã¯ãããã³ããã³å ç«
æå¶å€ã®ãããªåºç€æãªãŠãŒããå€ã§ããããšã
ãã»ãããšã¹ãã¢ãŒã«ã»ã·ãŒã»ããã©ãŒããã³ã
ã€ãŒã»ãšããã»ãŽããã¢ã«ããããªãŠãŒããæ§é¢
ç¯çã®æ²»çã«ãããæ€èšããã©ã³ã»ããã第巻ã
第278â279é ïŒ1984ïŒãã
ã§ãªãã®ã§ãäžè¬ã«åå çæ³ã¯äœ¿çšã§ããªããã±
ãŒã»ã¯ãªãŒã¬ãŒãããªãŠãŒããåŠã«ãããæ°ããª
æ²»çåçããMušnch.med.Wschrã第126å·»ã第
1084â1086é ïŒ1984ïŒããè¬ç©æäžæ²»çã«ãããŠã¯
åçš®ã®è¬å€ã䜿çšããããããã¯ïŒã€ã®çŸ€ã«åé¡
ããããšãã§ãããããªãã¡è¿ éã§ãããè¬å€ã
æåãããéã®ã¿äœçšããããšãã°ãµãªãã«é žã
ã€ã³ãã¡ã¿ã·ã³ããã³ã°ã«ã³ã³ã«ãã³ã€ãã®ãã
ãªå¯ŸçæãªãŠãŒããå€ãããã³ç åãæããŠæ²»ç
éå§åŸïŒãïŒé±éã§äœçšãçŸããããããã®å¹æ
ãæè¬åæ¢åŸã«ãæ°æéæç¶ãããããšãã°é
å¡©ãâããã·ã«ã¢ãã³ãã¯ãããã³ããã³å ç«
æå¶å€ã®ãããªåºç€æãªãŠãŒããå€ã§ããããšã
ãã»ãããšã¹ãã¢ãŒã«ã»ã·ãŒã»ããã©ãŒããã³ã
ã€ãŒã»ãšããã»ãŽããã¢ã«ããããªãŠãŒããæ§é¢
ç¯çã®æ²»çã«ãããæ€èšããã©ã³ã»ããã第巻ã
第278â279é ïŒ1984ïŒãã
αâIFNãçšããŠè¡ãªãããæ²»çã¯ããªãŠãŒã
ãæ§é¢ç¯çã«å¯ŸããŠã¯ç¡å¹ã§ãã€ãããšãŒã»ã«ãž
ã€ã³ããŒã«çãããªãŠãŒããæ§é¢ç¯çã®ã€ã³ã¿ã
ãšãã³æ²»çããã©ã³ã»ããã第巻ã第984é
ïŒ1979ïŒãããã®çµæã¯ãé©ããã«åœãããªããäœ
æ ãªãããªãŠãŒããæ§é¢ç¯çãå«ãæãçš®ã®ãªãŠ
ãŒããçæ£è ã«ãããŠã¯ãå çã€ã³ã¿ããšãã³ã
çæãããããã¯æ²»çäžå šãäœçšã瀺ãããæã
ã¯ãããæ£è ã®ç åã«ã€ãå眪ã«ãããªãããã
ãã§ããããžãšãŒã»ãžãšãŒã»ããã¯ã¹çããèªå®¶
å ç«ç ãæããæ£è ã®åŸªç°ç³»ã«ãããå ç«ã€ã³ã¿
ããšãã³ããN.Engl.J.Medã第301å·»ã第ïŒâïŒ
é ïŒ1979ïŒïŒãªãŒã»ãã€ãŒã»ãã¬ãã«çããå šèº«çŽ
ææ§çŒç¡ïŒé žæåæ§ã®ç°åžžçœè¡çã€ã³ã¿ããšãã³
ã®ããè¡æž ã«ãããååšãããµã€ãšã³ã¹ã第216
å·»ã第429â431é ïŒ1982ïŒïŒãšã ã»ãã°ã¬çãããª
ãŠãŒããæ§é¢ç¯çããã³é¢é£é害ã«ãããè¡æž ã
ãã³æ»æ¶²äžã®å ç«ã€ã³ã¿ããšãã³ããã¢ããŠã¢
ã«ã»ãªãŠãŒããã€ãã¯ã»ãã€ã¹ã«ãã·ãšã³ã第42
å·»ã第672â676é ïŒ1983ïŒïŒãšãŒã»ãšã ã»ã¢ãŒã
ã³ããã³ãžãšãŒã»ãžãšãŒã»ãã©ãŒããè¥å¹Žæ§é¢ç¯
çãæããæ£è ããã®è¡æž ããã³æ»æ¶²ã«ãããé ž
æåæ§ã®Î±âã€ã³ã¿ããšãããã¢ã«ã¹ãªãã¹ã»ã¢
ã³ãã»ãªãŠãŒãããºã ã第27å·»ã第582â585é
ïŒ1984ïŒïŒãã€ãŒã»ãªãŒã»ããŒãŒã³ãããçããã€
ã³ã¿ããšãã³ã¯å®éšæ»èçãæ¹èµ·ããããã«ãã
ãèªå®¶å ç«ç ãèªçºããããã¯ãªãã«ã«ã»ãªãŠãŒ
ããããžãŒã第ïŒå·»ã第361â364é ïŒ1984ïŒãã
ãæ§é¢ç¯çã«å¯ŸããŠã¯ç¡å¹ã§ãã€ãããšãŒã»ã«ãž
ã€ã³ããŒã«çãããªãŠãŒããæ§é¢ç¯çã®ã€ã³ã¿ã
ãšãã³æ²»çããã©ã³ã»ããã第巻ã第984é
ïŒ1979ïŒãããã®çµæã¯ãé©ããã«åœãããªããäœ
æ ãªãããªãŠãŒããæ§é¢ç¯çãå«ãæãçš®ã®ãªãŠ
ãŒããçæ£è ã«ãããŠã¯ãå çã€ã³ã¿ããšãã³ã
çæãããããã¯æ²»çäžå šãäœçšã瀺ãããæã
ã¯ãããæ£è ã®ç åã«ã€ãå眪ã«ãããªãããã
ãã§ããããžãšãŒã»ãžãšãŒã»ããã¯ã¹çããèªå®¶
å ç«ç ãæããæ£è ã®åŸªç°ç³»ã«ãããå ç«ã€ã³ã¿
ããšãã³ããN.Engl.J.Medã第301å·»ã第ïŒâïŒ
é ïŒ1979ïŒïŒãªãŒã»ãã€ãŒã»ãã¬ãã«çããå šèº«çŽ
ææ§çŒç¡ïŒé žæåæ§ã®ç°åžžçœè¡çã€ã³ã¿ããšãã³
ã®ããè¡æž ã«ãããååšãããµã€ãšã³ã¹ã第216
å·»ã第429â431é ïŒ1982ïŒïŒãšã ã»ãã°ã¬çãããª
ãŠãŒããæ§é¢ç¯çããã³é¢é£é害ã«ãããè¡æž ã
ãã³æ»æ¶²äžã®å ç«ã€ã³ã¿ããšãã³ããã¢ããŠã¢
ã«ã»ãªãŠãŒããã€ãã¯ã»ãã€ã¹ã«ãã·ãšã³ã第42
å·»ã第672â676é ïŒ1983ïŒïŒãšãŒã»ãšã ã»ã¢ãŒã
ã³ããã³ãžãšãŒã»ãžãšãŒã»ãã©ãŒããè¥å¹Žæ§é¢ç¯
çãæããæ£è ããã®è¡æž ããã³æ»æ¶²ã«ãããé ž
æåæ§ã®Î±âã€ã³ã¿ããšãããã¢ã«ã¹ãªãã¹ã»ã¢
ã³ãã»ãªãŠãŒãããºã ã第27å·»ã第582â585é
ïŒ1984ïŒïŒãã€ãŒã»ãªãŒã»ããŒãŒã³ãããçããã€
ã³ã¿ããšãã³ã¯å®éšæ»èçãæ¹èµ·ããããã«ãã
ãèªå®¶å ç«ç ãèªçºããããã¯ãªãã«ã«ã»ãªãŠãŒ
ããããžãŒã第ïŒå·»ã第361â364é ïŒ1984ïŒãã
幟ã€ãã®èšåºæ€æ»ã«ãããŠãçš®ã
ã®ãªãŠãŒãã
çæ£è ã®æ²»çã«éãã倩ç¶Î³âã€ã³ã¿ããšãã³ã®
ã¿ãªããçµæγâã€ã³ã¿ããšãã³ãå«æãã調補
ç©ãå°é泚å°ãããšçŒçãæç¶çã«é€å»ãããšå ±
ã«ãæ£è ã®éåæ§ãèããæ¹åããããšãäºæã
ãã«èŠãåºããããγâã€ã³ã¿ããšãã³ã¯ãçç
æ§ãªãŠãŒããçïŒå®æœäŸïŒãïŒïŒãé¢ç¯å€ãªãŠãŒ
ããçïŒå®æœäŸïŒããã³ïŒïŒããã³å€æ§ãªãŠãŒã
ãçïŒå®æœäŸïŒïŒã«ãããŠæ²»çäžæå¹ã§ãã€ãã
åŸæ¥èšåºäžç¢ºèªãããã€ã³ã¿ããšãã³ã®äœçšãã
ã¯æšæž¬ãããããã€ãã®çš®ã®ç æ°ã«ãããŠã€ã³ã¿
ããšãã³ã¯éäœçšããããšãèŠãããŠããã®ã§ã
äžèšå¹æã¯é©ç°çã§ããã
çæ£è ã®æ²»çã«éãã倩ç¶Î³âã€ã³ã¿ããšãã³ã®
ã¿ãªããçµæγâã€ã³ã¿ããšãã³ãå«æãã調補
ç©ãå°é泚å°ãããšçŒçãæç¶çã«é€å»ãããšå ±
ã«ãæ£è ã®éåæ§ãèããæ¹åããããšãäºæã
ãã«èŠãåºããããγâã€ã³ã¿ããšãã³ã¯ãçç
æ§ãªãŠãŒããçïŒå®æœäŸïŒãïŒïŒãé¢ç¯å€ãªãŠãŒ
ããçïŒå®æœäŸïŒããã³ïŒïŒããã³å€æ§ãªãŠãŒã
ãçïŒå®æœäŸïŒïŒã«ãããŠæ²»çäžæå¹ã§ãã€ãã
åŸæ¥èšåºäžç¢ºèªãããã€ã³ã¿ããšãã³ã®äœçšãã
ã¯æšæž¬ãããããã€ãã®çš®ã®ç æ°ã«ãããŠã€ã³ã¿
ããšãã³ã¯éäœçšããããšãèŠãããŠããã®ã§ã
äžèšå¹æã¯é©ç°çã§ããã
æ¬çºæã®ç®çã¯ãγâã€ã³ã¿ããšãã³ãå«æã
ããªãŠãŒããçæ²»çå€ãæäŸããããšã§ããã
ããªãŠãŒããçæ²»çå€ãæäŸããããšã§ããã
課é¡ã解決ããããã®æ段
äžèšã®ç®çãéæããããã«ãæ¬çºæã®æ²»çå€
ã¯ã倩ç¶Î³âã€ã³ã¿ããšãã³ïŒÎ³âIFNïŒããã³
çµæγâIFNãããªãγâã€ã³ã¿ããšãã³ãå«æ
ããã
ã¯ã倩ç¶Î³âã€ã³ã¿ããšãã³ïŒÎ³âIFNïŒããã³
çµæγâIFNãããªãγâã€ã³ã¿ããšãã³ãå«æ
ããã
倩ç¶Î³âIFNããã³çµæγâIFNã¯æ¬¡ã®ããã«
æäžããããšãã§ãããäžžè¬ãšããŠãæãã¯24æ
éãŸã§ã®æç¶çæµãšããŠã®éèå æäžãçèå
ïŒèé«å ããã³é¢ç¯åšå²ãå«ãïŒãæ»æ¶²å ãé¢ç¯
å ã骚èå ãç®äžãç®å ãè¢èå ãçµå£ãããã¯
å±éšçãªçµè·¯ã§ãããšãã°è»èãããã¯ã²ã«åºå€
ã«ãããŠç®èãžã®å¡åžæãã¯ç®èäžãžã®æµžéã«ã
ãæäžããããšãã§ããããããæäžåœ¢æ ã«ãã
ãŠãããã«åœæ¥è ã«åšç¥ãããæäžåœ¢æ ç©ã䜿çš
ããããšãã§ããã
æäžããããšãã§ãããäžžè¬ãšããŠãæãã¯24æ
éãŸã§ã®æç¶çæµãšããŠã®éèå æäžãçèå
ïŒèé«å ããã³é¢ç¯åšå²ãå«ãïŒãæ»æ¶²å ãé¢ç¯
å ã骚èå ãç®äžãç®å ãè¢èå ãçµå£ãããã¯
å±éšçãªçµè·¯ã§ãããšãã°è»èãããã¯ã²ã«åºå€
ã«ãããŠç®èãžã®å¡åžæãã¯ç®èäžãžã®æµžéã«ã
ãæäžããããšãã§ããããããæäžåœ¢æ ã«ãã
ãŠãããã«åœæ¥è ã«åšç¥ãããæäžåœ¢æ ç©ã䜿çš
ããããšãã§ããã
å
šãŠã®æäžã«éããæ£è
ã®çç¶çšåºŠã«ãããã
æ¯æ¥ãŸãã¯æ°æ¥ã«ãããïŒåãããã¯æ°åã«åå²
ããŠã200åœéåäœïŒI.E.ïŒã2000000åœéåäœã®
éã§æäžããããæ°æ¥éã®æäžã«å¯ŸããŠã¯ïŒåã
ããã¯ãã以äžã®æäžéã¯æ¬¡ã®ããã«æäžããã
ãšãã§ããïŒ (a) æ¯æ¥é£ç¶ããŠã (b) ïŒãïŒæ¥éå šéšã (c) ïŒé±éã«ïŒåã (d) ïŒãïŒé±éå šéšã (e) ïŒã±æã«ïŒåããŸã㯠(f) çŒçãçºçããéœåºŠã
æ¯æ¥ãŸãã¯æ°æ¥ã«ãããïŒåãããã¯æ°åã«åå²
ããŠã200åœéåäœïŒI.E.ïŒã2000000åœéåäœã®
éã§æäžããããæ°æ¥éã®æäžã«å¯ŸããŠã¯ïŒåã
ããã¯ãã以äžã®æäžéã¯æ¬¡ã®ããã«æäžããã
ãšãã§ããïŒ (a) æ¯æ¥é£ç¶ããŠã (b) ïŒãïŒæ¥éå šéšã (c) ïŒé±éã«ïŒåã (d) ïŒãïŒé±éå šéšã (e) ïŒã±æã«ïŒåããŸã㯠(f) çŒçãçºçããéœåºŠã
å®éã®äœ¿çšã«ã€ããŠã¯ãããšãã°20000ã
2000000 I.E.ïŒããªãã¡çŽïŒã200ÎŒgïŒã®Î³âIFN
ãšããå°éã®æäžéã«ããè©Šæããéå§ããããš
ãæšå¥šãããã
2000000 I.E.ïŒããªãã¡çŽïŒã200ÎŒgïŒã®Î³âIFN
ãšããå°éã®æäžéã«ããè©Šæããéå§ããããš
ãæšå¥šãããã
γâã€ã³ã¿ããšãã³èª¿è£œç©ã®å¹æãé«ããã«
ã¯ã次ã®ç©è³ªãããã«æ·»å ããããšãã§ããïŒ (a) ä»ã®ã€ã³ã¿ããšãã³ããã³ïŒãŸãã¯çœè¡çã«
ããçæãããããã¯éºäŒåå·¥åŠæ³ã«ããçæ
ãããä»ã®çŽ°èåªäœã (b) åŸæ¥æ²»çã«äœ¿çšãããŠããæãªãŠãŒããå€ã
ã¯ã次ã®ç©è³ªãããã«æ·»å ããããšãã§ããïŒ (a) ä»ã®ã€ã³ã¿ããšãã³ããã³ïŒãŸãã¯çœè¡çã«
ããçæãããããã¯éºäŒåå·¥åŠæ³ã«ããçæ
ãããä»ã®çŽ°èåªäœã (b) åŸæ¥æ²»çã«äœ¿çšãããŠããæãªãŠãŒããå€ã
åçš®æè¬åœ¢æ
ç©ãäœæããã«ã¯ãåœæ¥è
ã«åšç¥
ã®å©å€ã䜿çšãããã
ã®å©å€ã䜿çšãããã
以äžãå®æœäŸã«ããæ¬çºæã説æããã
å®æœäŸ ïŒ
æ£è
ïŒLu.ç·æ§ã
蚺æïŒ10幎é以äžã«ãããéçã®æ
¢æ§å€çºé¢ç¯
çãæããã³è¶³ã«ãããå€åœ¢ãèšåºæ€æ»ã®
ééåæ§ãªããåŸæ¥çŒçã®æ¹åå šããªãã
çãæããã³è¶³ã«ãããå€åœ¢ãèšåºæ€æ»ã®
ééåæ§ãªããåŸæ¥çŒçã®æ¹åå šããªãã
ç©è³ªïŒããçœè¡çããã®ããγâIFN補å€ã
æäžæ¹æ³ïŒç®äž
çæ³ïŒ
æ²»çæ¥ æäžé
1. 0.1Ã106 I.E.
2. 0.5Ã106 I.E.
3. 0.5Ã106 I.E.
4. 1.0Ã106 I.E.
5. 1.0Ã106 I.E.
8. 1.5Ã106 I.E.
9. 1.5Ã106 I.E.
10. 1.5Ã106 I.E.
11. 1.5Ã106 I.E.
çµæïŒæ²»çïŒæ¥ç®ã«äžè¢ã«ãããçŒçã®çžåœãªæ¹
åã瀺ããããæ²»ç11æ¥ä»¥éãæ£è ã¯å®å š
ã«çŒçããªããªã€ããæ£è ã¯æ©è¡å¯èœãšãª
ãããã€é段ãæãããšããã§ãããæç
æ§ã¯æ¶å€±ããã
åã瀺ããããæ²»ç11æ¥ä»¥éãæ£è ã¯å®å š
ã«çŒçããªããªã€ããæ£è ã¯æ©è¡å¯èœãšãª
ãããã€é段ãæãããšããã§ãããæç
æ§ã¯æ¶å€±ããã
å®æœäŸ ïŒ
æ£è
ïŒZi.ç·æ§ã
蚺æïŒäž¡æã«ãããå€åœ¢ã䌎ãªãéçã®æ
¢æ§å€çº
é¢ç¯çã
é¢ç¯çã
ç©è³ªïŒããçœè¡çããã®ããγâIFN補å€ã
æäžæ¹æ³ïŒç®äž
çæ³ïŒ
æ²»çæ¥ æäžé
1. 0.5Ã106 I.E.
2. 0.5Ã106 I.E.
3. 0.5Ã106 I.E.
4. 0.5Ã106 I.E.
5. 0.5Ã106 I.E.
8. 1.0Ã106 I.E.
9. 1.0Ã106 I.E.
10. 1.0Ã106 I.E.
çµæïŒ0.5Ã106I.E.ã«ããæ²»çã§çŒçã®çžåœãªæ¹
åãªè¡šããã1.0Ã106I.E.ã«ããæ²»çã§æ£
è ã¯å®å šã«çŒçããªããªã€ããæ£è ã¯æ²»ç
ã®éå§ã«éãæé«ïŒåéã«ãããè»æ€ åã§
æ©è¡å¯èœãšãªã€ããæ²»çïŒæ¥ç®ä»¥éãïŒÃ
20åéã«ãããå¯èœãšãªã€ããæ£è ã¯å埩
ãèªèŠãããã€ãã¯ãã³ãŒããŸã³ãå¿ èŠãš
ããªãã€ããæ£è ã¯æ²»çéå§åŸ17æ¥ç®ã«èš
åºãã解æŸãããããã®æ£è ã¯éé¢æ¥ã«çŒ
çããªããªãããã®éåæ§ã¯ç¢ºå®ãšãªãã
é¢ç¯ã«ã¯ãã¯ãæçæ§ãå šãååšããªãã€
ãã
åãªè¡šããã1.0Ã106I.E.ã«ããæ²»çã§æ£
è ã¯å®å šã«çŒçããªããªã€ããæ£è ã¯æ²»ç
ã®éå§ã«éãæé«ïŒåéã«ãããè»æ€ åã§
æ©è¡å¯èœãšãªã€ããæ²»çïŒæ¥ç®ä»¥éãïŒÃ
20åéã«ãããå¯èœãšãªã€ããæ£è ã¯å埩
ãèªèŠãããã€ãã¯ãã³ãŒããŸã³ãå¿ èŠãš
ããªãã€ããæ£è ã¯æ²»çéå§åŸ17æ¥ç®ã«èš
åºãã解æŸãããããã®æ£è ã¯éé¢æ¥ã«çŒ
çããªããªãããã®éåæ§ã¯ç¢ºå®ãšãªãã
é¢ç¯ã«ã¯ãã¯ãæçæ§ãå šãååšããªãã€
ãã
å®æœäŸ ïŒ
æ£è
ïŒI.Jaš.女æ§ã
蚺æïŒè¡æž
é°æ§ã®ãªãŠãŒããæ§å€çºé¢ç¯çã
貧è¡ãèèã®å±éšççµç¯å¢æ®ã
ç©è³ªïŒã€ãŒã»ã³ãªããã®ããγâIFN補å€ã
æäžæ¹æ³ïŒçèå
çæ³ïŒ
æ²»çæ¥ æäžé
1. 100ÎŒg掻æ§ç©è³ª
2. 100ÎŒg掻æ§ç©è³ª
3. 100ÎŒg掻æ§ç©è³ª
4. 100ÎŒg掻æ§ç©è³ª
5. 100ÎŒg掻æ§ç©è³ª
6. 100ÎŒg掻æ§ç©è³ª
7. 100ÎŒg掻æ§ç©è³ª
8. 100ÎŒg掻æ§ç©è³ª
11. 175ÎŒg掻æ§ç©è³ª
12. 175ÎŒg掻æ§ç©è³ª
13. 50ÎŒg掻æ§ç©è³ª
14. 50ÎŒg掻æ§ç©è³ª
çµæïŒæ²»çåæ¥ç®ã«çŒçã匷ããªã€ãåŸãæ£è
ã¯
æ²»çïŒæ¥ç®ã«åããŠçŒçããªããªã€ããæ²»
çãããã«ç¶ãããšãçŒçã¯ããã«çæé
ãšãªã€ããéããªãæ£è ã«ã¯æ¯é±ïŒå
10ÎŒgã®æŽ»æ§ç©è³ªãçèå 泚å°ããããã«
ãªã€ããæ£è ã¯ãã®è¬å€ã«è¯å¥œã«èããã
ã以æ¥åã³çŒçããªããªã€ãã
æ²»çïŒæ¥ç®ã«åããŠçŒçããªããªã€ããæ²»
çãããã«ç¶ãããšãçŒçã¯ããã«çæé
ãšãªã€ããéããªãæ£è ã«ã¯æ¯é±ïŒå
10ÎŒgã®æŽ»æ§ç©è³ªãçèå 泚å°ããããã«
ãªã€ããæ£è ã¯ãã®è¬å€ã«è¯å¥œã«èããã
ã以æ¥åã³çŒçããªããªã€ãã
å®æœäŸ ïŒ
æ£è
ïŒH.L.女æ§ã
蚺æïŒïŒå¹Žéã«ããã確å®ãªãªãŠãŒããæ§é¢ç¯
çãæãè °ãèãèžé¢ç¯ããã³æé¢ç¯ã«çŒ
çãããæ£è ã¯éããã³ãã¬ãããŸãã³ã«
察ãæåæ§ãªãã
çãæãè °ãèãèžé¢ç¯ããã³æé¢ç¯ã«çŒ
çãããæ£è ã¯éããã³ãã¬ãããŸãã³ã«
察ãæåæ§ãªãã
ç©è³ªïŒã€ãŒã»ã³ãªããã®ããγâIFN補å€ã
æäžïŒç®äž
æäžéïŒæ²»çéå§ãšããŠæ¯æ¥ïŒåã®250ÎŒgãæç¶
æ²»çãšããŠã®æ¯æ¥ïŒåã®50ÎŒgã
æ²»çãšããŠã®æ¯æ¥ïŒåã®50ÎŒgã
çµæïŒæ²»çïŒæ¥åŸã«æ£è
ã¯çŒçããªããªãããã€
éåæ§ãèªç±ãšãªã€ããæ²»çãæç¶ãã
ãšããªãŠãŒããæ§é¢ç¯çã®èšåºæ瞟ãçžåœ
ã«æ¹åããããã€æç¶ããããæ£è ã¯çŒç
ãªãã®ç¶æ ãç¶æããã
éåæ§ãèªç±ãšãªã€ããæ²»çãæç¶ãã
ãšããªãŠãŒããæ§é¢ç¯çã®èšåºæ瞟ãçžåœ
ã«æ¹åããããã€æç¶ããããæ£è ã¯çŒç
ãªãã®ç¶æ ãç¶æããã
å®æœäŸ ïŒ
æ£è
ïŒW.D.女æ§ã
蚺æïŒïŒé±éåããäžè
è©ç²éªšé¢ç¯åšå²çã
ç©è³ªïŒããçœè¡çããã®ããγâIFN補å€ã
æäžæ¹æ³ããã³çæ³ïŒ
ïŒæ¥ïŒåç®äžïŒ0.5Ã106I.E.ïŒ
çµæïŒæ£è
ã¯æ°åé以å
ã«çŒçããªããªã€ããã
ã以æ¥ãçŒçã¯ãã¯ãçããªãã€ãã
ã以æ¥ãçŒçã¯ãã¯ãçããªãã€ãã
å®æœäŸ ïŒ
æ£è
ïŒL.L.ç·æ§ã
蚺æïŒåº§éªšç¥çµçL5ïŒS1å³åŽãïŒé±éåãã骚
å€åçã
å€åçã
ç©è³ªïŒããçœè¡çããã®ããγâIFN補å€ã
æäžæ¹æ³ïŒèæ€æ
çæ³ïŒ
æ²»çæ¥ æäžé
1. 0.5Ã106 I.E.
21. 0.5Ã106 I.E.
çµæïŒæåã®æ³šå°ä»¥åŸãæ£è
ã¯ïŒæ¥éã«ããã第
ïŒåã®æ³šå°ããçŸåšãŸã§ïŒæåã®æ²»çæ¥ã
ãïŒã±æïŒçŒçããªãã€ãã
ïŒåã®æ³šå°ããçŸåšãŸã§ïŒæåã®æ²»çæ¥ã
ãïŒã±æïŒçŒçããªãã€ãã
çºæã®å¹æ
åŸæ¥ãªãŠãŒããçã«é©åãªæ²»çå€ããªãã€ã
ããæ¬çºæã®Î³âã€ã³ã¿ããšãã³ãå«æããæ²»ç
å€ã«ãããäŸãã°ããªãŠãŒããçæ£è ã«å°é泚å°
ãããšçŒçãæç¶çã«é€å»ãããšå ±ã«ãæ£è ã®é
åæ§ãèããæ¹åã§ãããŸãççæ§ãªãŠãŒããç
ïŒå®æœäŸ13ïŒãé¢ç¯å€ãªãŠãŒããçïŒå®æœäŸïŒãã
ã³ïŒïŒãããã³å€æ§ãªãŠãŒããçïŒå®æœäŸïŒïŒã«
ãããŠæ²»çäžæå¹ã§ãããçš®ã ã®ãªãŠãŒããçã«
察ããŠæ¥µããŠåªããç¹å¹çãªæ²»çå€ãæäŸåºæ¥
ãã
ããæ¬çºæã®Î³âã€ã³ã¿ããšãã³ãå«æããæ²»ç
å€ã«ãããäŸãã°ããªãŠãŒããçæ£è ã«å°é泚å°
ãããšçŒçãæç¶çã«é€å»ãããšå ±ã«ãæ£è ã®é
åæ§ãèããæ¹åã§ãããŸãççæ§ãªãŠãŒããç
ïŒå®æœäŸ13ïŒãé¢ç¯å€ãªãŠãŒããçïŒå®æœäŸïŒãã
ã³ïŒïŒãããã³å€æ§ãªãŠãŒããçïŒå®æœäŸïŒïŒã«
ãããŠæ²»çäžæå¹ã§ãããçš®ã ã®ãªãŠãŒããçã«
察ããŠæ¥µããŠåªããç¹å¹çãªæ²»çå€ãæäŸåºæ¥
ãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ Î³âã€ã³ã¿ããšãã³ãå«æãããªãŠãŒããç
æ²»çå€ã ïŒ ççæ§ãªãŠãŒããçãæ²»çããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé èšèŒã®æ²»çå€ã ïŒ æ ¢æ§å€çºé¢ç¯çïŒãªãŠãŒããæ§é¢ç¯çïŒãæ²»
çããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ²»çå€ã ïŒ è¥å¹Žæ§æ ¢æ§é¢ç¯çãæ²»çããç¹èš±è«æ±ã®ç¯å²
第ïŒé èšèŒã®æ²»çå€ã ïŒ ä¹Ÿç¬æ§é¢ç¯çãæ²»çããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é èšèŒã®æ²»çå€ã ïŒ é¢ç¯å€ãªãŠãŒããçïŒè»éšãªãŠãŒããçïŒã
æ²»çããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ²»çå€ã ïŒ çèãªãŠãŒããçããã³äžè è©è骚é¢ç¯åšå²
çãæ²»çããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ²»ç
å€ã ïŒ å€æ§ãªãŠãŒããçãæ²»çããç¹èš±è«æ±ã®ç¯å²
第ïŒé èšèŒã®æ²»çå€ã ïŒ çŽ ææ§çŒç¡ãæ²»çããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
èšèŒã®æ²»çå€ã ïŒïŒ ç®èççãæ²»çããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
èšèŒã®æ²»çå€ã ïŒïŒ 硬ç®çãæ²»çããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èš
èŒã®æ²»çå€ã ïŒïŒ γâã€ã³ã¿ããšãã³ããã现èã«ãããŸã
ã¯éºäŒåå·¥åŠçæ¹æ³ã«ããçç£ããããšãç¹åŸŽãš
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ²»çå€ã ïŒïŒ γâã€ã³ã¿ããšãã³å«ææ²»çå€ã«å ããä»
ã®ã€ã³ã¿ããšãã³ããã³ïŒãŸãã¯çœè¡çã«ããç
æãããããã¯éºäŒåå·¥åŠçæ¹æ³ã«ããçæãã
ãä»ã®çŽ°èåªäœããå«æããããšãç¹åŸŽãšããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ²»çå€ã ïŒïŒ éèå ãçèå ãé¢ç¯å ãé¢ç¯æ¶²å ã骚è
å ãç®äžãç®å ãè¢èå ãå£åŸçãŸãã¯å±éšççµ
è·¯ã«ãŠæäžããæäžåœ¢æ ã§ããããšãç¹åŸŽãšãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒïŒé ã®ããããã«èš
èŒã®Î³âã€ã³ã¿ããšãã³å«æã®æ²»çå€ã ïŒïŒ ããªããããæ²»çå€ã«ã€ãç¥ãããæäžåœ¢
æ ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®æ²»çå€ã ïŒïŒ æäžãããåã ã®æäžéã200åœéåºæºå
äœïŒI.E.ïŒã2000000I.E.ïŒçŽ20ngã20mgã«çžåœïŒ
ã®Î³âã€ã³ã¿ããšãã³ãå«æããããšãç¹åŸŽãšã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒïŒé ã®ããããã«
èšèŒã®Î³âã€ã³ã¿ããšãã³å«æã®æ²»çå€ã
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3436638.5 | 1984-10-05 | ||
DE3436638A DE3436638C2 (de) | 1984-10-05 | 1984-10-05 | Verwendung von Interferon-gamma (IFN-gamma) enthaltenden PrÀparationen zur Behandlung rheumatischer Erkrankungen |
EP85107490.6 | 1985-06-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6191135A JPS6191135A (ja) | 1986-05-09 |
JPH0544930B2 true JPH0544930B2 (ja) | 1993-07-07 |
Family
ID=6247225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60188689A Granted JPS6191135A (ja) | 1984-10-05 | 1985-08-29 | γâã€ã³ã¿ããšãã³ïŒÎ³âïŒãå«æãããªãŠâããçæ²»çå€ |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0180737B1 (ja) |
JP (1) | JPS6191135A (ja) |
AT (1) | ATE45675T1 (ja) |
DE (2) | DE3436638C2 (ja) |
ZA (1) | ZA857721B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5910304A (en) * | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
DE3519361A1 (de) * | 1985-05-30 | 1986-12-04 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | (gamma)-ifn als wirkstoff zur hemmung (verhinderung) von abbauprozessen im knochen |
WO1987007842A1 (en) * | 1986-06-17 | 1987-12-30 | Biogen N.V. | Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents and methods for treating diseases |
CA1320905C (en) * | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
AU2855189A (en) * | 1988-01-25 | 1989-07-27 | Baker Cummins Dermatologicals, Inc. | Method of treating fibrotic disorders |
DE4238159A1 (en) * | 1992-11-12 | 1993-04-29 | Josef Dr Med Mueller | Treatment of prim. chronic polyarthritis and diabetes mellitus - comprises administration of gamma-interferon |
JP2850293B2 (ja) * | 1996-10-25 | 1999-01-27 | æ ªåŒäŒç€Ÿæåçç©ååŠç 究æ | γâã€ã³ã¿ãŒãã§ãã³æåæ§çŸæ£å€ |
US6299871B1 (en) * | 1998-07-24 | 2001-10-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Orally-administrable therapeutic and/or prophylactic agent for HTLV-1-related diseases |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5527168A (en) * | 1978-04-11 | 1980-02-27 | Verronmay Ltd | Drug composition |
JPS5598118A (en) * | 1979-01-18 | 1980-07-25 | Hayashibara Takeshi | Preparation of type-2 interferon and drug containing the same |
CA1190148A (en) * | 1981-10-13 | 1985-07-09 | Samuel S. Asculai | Interferon-containing compositions |
DE3278234D1 (en) * | 1981-10-13 | 1988-04-21 | Exovir Inc | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis |
AU561343B2 (en) * | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
DE3380200D1 (en) * | 1982-09-16 | 1989-08-24 | William Alvin Carter | Anti-proliferative action of dsnras on tumor cells |
EP0107498B1 (en) * | 1982-10-25 | 1990-05-16 | Genentech, Inc. | Synergistic human interferon activity |
US4483849A (en) * | 1983-01-07 | 1984-11-20 | Carter William A | Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product |
JP3108538B2 (ja) * | 1992-08-13 | 2000-11-13 | æŸäžé»å·¥æ ªåŒäŒç€Ÿ | å¹³é¢ãã©ã³ã¹ |
-
1984
- 1984-10-05 DE DE3436638A patent/DE3436638C2/de not_active Expired - Lifetime
-
1985
- 1985-08-29 JP JP60188689A patent/JPS6191135A/ja active Granted
- 1985-09-04 AT AT85111183T patent/ATE45675T1/de not_active IP Right Cessation
- 1985-09-04 EP EP85111183A patent/EP0180737B1/de not_active Expired
- 1985-09-04 DE DE8585111183T patent/DE3572441D1/de not_active Expired
- 1985-10-07 ZA ZA857721A patent/ZA857721B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP0180737A3 (en) | 1986-05-28 |
EP0180737B1 (de) | 1989-08-23 |
EP0180737A2 (de) | 1986-05-14 |
ZA857721B (en) | 1986-09-24 |
DE3572441D1 (en) | 1989-09-28 |
DE3436638C2 (de) | 1992-10-08 |
JPS6191135A (ja) | 1986-05-09 |
ATE45675T1 (de) | 1989-09-15 |
DE3436638A1 (de) | 1986-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2310931T3 (es) | Analogos de interferon alfa humano de baja toxicidad. | |
US5145677A (en) | Process for treatment of diseases | |
TW400233B (en) | Pharmaceutical compositions comprising IL-12 antagonists for treating autoimmune diseases | |
ES2243990T3 (es) | Composicion de interferon hibrido y procedimiento de uso. | |
JPH07503851A (ja) | æ¹è¯ã€ã³ã¿ãŒãã§ãã³åã³ããã®æ«æ¢¢è¡æ¶²çœè¡çããã®ãã®è£œé æ¹æ³ | |
US4946674A (en) | Process for treatment of rheumatic diseases | |
US5554515A (en) | Preparation of a monoclonal antibody specific to human myelomonocyte interferon-gamma | |
US5582822A (en) | Treatment of leukemia using interleukin 2 | |
US20120020916A1 (en) | Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases | |
EP0696594B1 (en) | Human interleukin 6 inhibitor | |
ES2243942T3 (es) | Isoforma intracelular del antagonista del receptor de la interleuquina. | |
JPH0544930B2 (ja) | ||
EP0311616B1 (en) | Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents for treating diseases | |
US20160175390A1 (en) | Antiviral agent comprising recombinant mistletoe lectins | |
JP2662214B2 (ja) | äœæäžéã«ãŠããã®çèçž®æ§åŽçŽ¢ç¡¬åçã系統çã«æ²»çããããã®Î³âã€ã³ã¿ãŒãã§ãã³å«æçµæç© | |
Crockett et al. | Side effects and toxicity of interferon in the treatment of recurrent respiratory papillomatosis | |
PT588177E (pt) | Proteina de ligacao dos interferoes alfa/beta sua preparacao e composicoes farmaceuticas que a contem | |
JP4023863B2 (ja) | ïœâïŒãå«ãè¡æž å°¿é žå€äœäžå€ | |
WO1991008754A1 (en) | Medicinal application of m-csf | |
AU732053B2 (en) | Agents for the prevention and/or treatment of radiation-induced disorders | |
WO1993002692A1 (en) | Method of combatting hiv infections | |
TRAUB et al. | Isolation of Two Species of Human Lymphoblastoid (Namalva) Cell-Derived Interferon that Differ in Rates of Clearance, Size, and Cell Specificity. | |
EP0205629A1 (de) | Verwendung von Interferon-gamma (IFN-gamma) enthaltenden PrÀparationen zur Behandlung rheumatischer Erkrankungen | |
JP2697725B2 (ja) | æªæ§è «çæ²»ççšããã | |
JP2004182683A (ja) | æ°èŠãªççæ§çŸæ£æ¹åå€ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |